Oligonucleotides having a nucleotide sequence complementary to nucleotidenumbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) andtherapeutic agents for muscular dystrophy comprising such oligonucleotides.